适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Abivax
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.Moderately to severely active ulcerative colitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-509226-21-00Abivax24
进行中（未招募）
1 期
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.Moderately to severely active ulcerative colitisCTIS2024-514561-20-00Abivax48
进行中（未招募）
1 期
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouthCTIS2023-508030-33-00Sanofi-Aventis Recherche & Developpement13
进行中（未招募）
1 期
A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infectiochronic hepatitis B virus infection (cHBV)CTIS2024-511051-18-00Assembly Biosciences Inc.50
进行中（未招募）
1 期
ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.metastatic/advanced breast cancerMedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10072737Term: Advanced breast cancer Class: 10029104CTIS2023-507074-40-00Pfizer Inc.12